Sonnet Biotherapeutics Holdings Inc (SONN)

12:57 PM

Sonnet BioTherapeutics Says Ovarian Cancer Drug Showed 'Positive' Safety Data in Phase 1b/2a Trial; Shares Up - MarketScreener

12:57 PM

09:31 AM

Sonnet says SON-1010 demonstrates ‘strong safety profile’ in atezolizumab combo - TipRanks

09:31 AM

09:18 AM

Sonnet BioTherapeutics advances in cancer trial - Investing.com

09:18 AM

09:03 AM

Sonnet'S Son-1010 Demonstrates A Strong Safety Profile In Combination With Atezolizumab For Treatment Of Platinum-Resistant Ovarian Cancer - MarketScreener

09:03 AM

09:01 AM

Sonnet’s SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose - GlobeNewswire

09:01 AM

Apr 01, 2025

Sonnet Announces Release of Corporate Update Video - GlobeNewswire

Apr 01, 2025

Apr 01, 2025

Sonnet BioTherapeutics appoints interim CEO and new president By Investing.com - Investing.com South Africa

Apr 01, 2025

Apr 01, 2025

Sonnet BioTherapeutics appoints interim CEO and new president - Investing.com

Apr 01, 2025

Apr 01, 2025

Pilot Killed In Franklin Twp Plane Crash Was CEO Of Cancer-Focused Biotech Company - dailyvoice.com

Apr 01, 2025

Apr 01, 2025

Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D. - citybiz

Apr 01, 2025

Apr 01, 2025

Sonnet BioTherapeutics appoints interim CEO after founder’s death - Investing.com

Apr 01, 2025

Apr 01, 2025

Sonnet Announces The Passing Of Founder And CEO Pankaj Mohan - MarketScreener

Apr 01, 2025

Apr 01, 2025

Leadership Change at Sonnet BioTherapeutics: Founder Passes, New Executive Team Steps In - Stock Titan

Apr 01, 2025

Mar 30, 2025

Chardan Capital Reaffirms Buy Rating for Sonnet BioTherapeutics (NASDAQ:SONN) - Defense World

Mar 30, 2025

Mar 29, 2025

Sonnet BioTherapeutics’ (SONN) Buy Rating Reaffirmed at Chardan Capital - The AM Reporter

Mar 29, 2025

Mar 28, 2025

SONN stock touches 52-week low at $1.28 amid market challenges - Investing.com Australia

Mar 28, 2025

Mar 27, 2025

Sonnet BioTherapeutics Successfully Completes First Safety - GlobeNewswire

Mar 27, 2025

Mar 26, 2025

Sonnet BioTherapeutics Successfully Completes First Safety Review Of SON-1010 In Combination With Trabectedin In Certain Sarcomas - MarketScreener

Mar 26, 2025

Mar 26, 2025

Clinical Trial Success: New Cancer Drug Combo Shows 83% Disease Control in Sarcoma Patients - Stock Titan

Mar 26, 2025

Mar 21, 2025

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) Short Interest Up 16.4% in February - Defense World

Mar 21, 2025

Mar 19, 2025

Sonnet BioTherapeutics secures new IL-18 patent - Investing.com

Mar 19, 2025

Mar 19, 2025

Sonnet BioTherapeutics secures new IL-18 patent By Investing.com - Investing.com South Africa

Mar 19, 2025

Mar 19, 2025

Sonnet BioTherapeutics Secures Second Patent for IL-18 Variant - TipRanks

Mar 19, 2025

Mar 19, 2025

Sonnet BioTherapeutics Receives Notice of Allowance for - GlobeNewswire

Mar 19, 2025

Mar 19, 2025

Major Patent Win: Sonnet's Revolutionary IL-18 Cancer Treatment Shows Superior Binding Properties - StockTitan

Mar 19, 2025

Mar 19, 2025

Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein - The Manila Times

Mar 19, 2025

Mar 11, 2025

Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewswire

Mar 11, 2025

Mar 11, 2025

Sonnet BioTherapeutics Holdings, Inc. Announces Availability of On-Demand Video Webcast Following Virtual Investor "Top 5 for ‘25" Conference - Nasdaq

Mar 11, 2025

Mar 11, 2025

Sonnet Bio CEO Unveils 5 Game-Changing Developments Coming in 2025 - StockTitan

Mar 11, 2025

Mar 11, 2025

XRP Plunges as Recession Panic and Crypto Summit Fallout Slam Investors - The Globe and Mail

Mar 11, 2025

Mar 07, 2025

Sonnet BioTherapeutics Stock Price, Quotes and Forecasts - Benzinga

Mar 07, 2025

Mar 04, 2025

SONN stock touches 52-week low at $1.33 amid market challenges - Investing.com UK

Mar 04, 2025

Feb 27, 2025

Sonnet BioTherapeutics Provides Fiscal Year 2022 First Quarter Business and Earnings Update - ACCESS Newswire

Feb 27, 2025

Feb 26, 2025

Sonnet BioTherapeutics Highlights Promising SON-1010 Data - TipRanks

Feb 26, 2025

Feb 26, 2025

Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors - The Manila Times

Feb 26, 2025

Feb 26, 2025

Sonnet BioTherapeutics Presents Innovative FHAB® Platform Data at 2025 AACR:IO Conference - Nasdaq

Feb 26, 2025

Feb 26, 2025

Sonnet BioTherapeutics Presents Compilation of Data - GlobeNewswire

Feb 26, 2025

Feb 26, 2025

Can This Immunotherapy Beat Solid Tumors? Sonnet's SON-1010 Shows 48% Clinical Benefit - StockTitan

Feb 26, 2025

Feb 21, 2025

Sonnet BioTherapeutics Announces Availability of Proprietary ADC Platform for Drug Discovery Partnerships - The AM Reporter

Feb 21, 2025

Feb 20, 2025

Sonnet BioTherapeutics advances novel ADC platform By Investing.com - Investing.com Australia

Feb 20, 2025

Feb 19, 2025

Sonnet BioTherapeutics advances novel ADC platform - Investing.com

Feb 19, 2025

Feb 19, 2025

SONN stock touches 52-week low at $1.38 amid market challenges - Investing.com India

Feb 19, 2025

Feb 19, 2025

Sonnet Biotherapeutics' Proprietary ADC Platform Available For Drug Discovery Partnerships - Marketscreener.com

Feb 19, 2025

Feb 19, 2025

Sonnet BioTherapeutics Announces That Its Proprietary - GlobeNewswire

Feb 19, 2025

Feb 19, 2025

Sonnet BioTherapeutics Advances Antibody Drug Conjugate Platform - TipRanks

Feb 19, 2025

Feb 19, 2025

2 Hot Growth Stocks Poised for Gains of Up to 370%, According to Wall Street - The Globe and Mail

Feb 19, 2025

Feb 19, 2025

Can This New ADC Platform Challenge Established Cancer Drugs? Preclinical Data Shows Promise - StockTitan

Feb 19, 2025